Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.14068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Sophia Krasny und 8 weiteren Autor:innen. Beteiligte Einrichtung: Scripps Research Institute, La Jolla, California, USA. Hauptthemen laut MEDLINE: Down Syndrome, Positron-Emission Tomography, Amyloid beta-Peptides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NICHD NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
INTRODUCTION Trisomy 21, or Down syndrome (DS), predisposes individuals to early‐onset Alzheimer's disease (AD). While monoclonal antibodies (mAbs) targeting amyloid are approved for older AD patients, their efficacy in DS remains unexplored. This study examines amyloid positron emission tomography (PET) positivity (A+), memory function, and clinical status across ages in DS to guide mAb trial designs. METHODS Cross‐sectional data from the Alzheimer Biomarker Consortium–Down Syndrome (ABC‐DS) was analyzed. PET amyloid beta in Centiloids classified amyloid status using various cutoffs. Episodic memory was assessed using the modified Cued Recall Test, and clinical status was determined through consensus processes. RESULTS Four hundred nine DS adults (mean age = 44.83 years) were evaluated. A+ rates increased with age, with mean amyloid load rising significantly. Memory decline and cognitive impairment are also correlated with age. DISCUSSION These findings emphasize the necessity of tailoring mAb trials for DS, considering age‐related AD characteristics. Highlights There is rapid increase in prevalence of amyloid beta (Aβ) positron emission tomography (PET) positivity in Down syndrome (DS) after the age of 40 years. Aβ PET positivity thresholds have significant impact on prevalence rates in DS. There is a significant lag between Aβ PET positivity and clinical symptom onset in DS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scripps Research Institute, La Jolla, California, USA.
- Department of Neurology, Washington University, Saint Louis, Missouri, USA.
- Waisman Center, University of Wisconsin, Madison, Wisconsin, USA.
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Alzheimer's Therapeutic Research Institute, Keck School of Medicine of University of Southern California, San Diego, California, USA.
Förderung
- NIA NIH HHS
- NICHD NIH HHS
- NCATS NIH HHS
- National Centralized Repository for Alzheimer Disease and Related Dementias
- the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- The Alzheimer's Disease Research Centers
- National Institute on Aging
- National Center for Advancing Translational Sciences
Zitieren
APA
Krasny, S., Yan, C., Hartley, S. L., Handen, B. L., Wisch, J. K., Boehrwinkle, A. H., Ances, B. M., Rafii, M. S., & ABC‐DS consortium (2024). Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14068
Vancouver
Krasny S, Yan C, Hartley SL, Handen BL, Wisch JK, Boehrwinkle AH, et al. Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14068
BibTeX
@article{Krasny2024,
author = {Krasny, Sophia and Yan, Cynthia and Hartley, Sigan L and Handen, Ben L and Wisch, Julie K and Boehrwinkle, Anna H and Ances, Beau M and Rafii, Michael S and ABC‐DS consortium, ABC‐DS consortium},
title = {Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.14068}
}
EUVIMED